Huidong (Gena) Wang's questions to Vir Biotechnology Inc (VIR) leadership • Q1 2025
Question
Huidong (Gena) Wang asked about the rationale for Alnylam's decision not to opt into the profit-sharing arrangement for elebsiran and inquired about the expected timing for the next data update from VIR's oncology programs.
Answer
Marianne De Backer (Executive) explained that Alnylam's decision was based on its own strategic portfolio prioritization and was made before VIR's latest HBV functional cure data was available. Regarding the oncology update, she stated that new data would be shared once more mature results from higher dose levels are available, likely at a future medical congress or a focused investor event.